New pill shows promise for tough blood cancers in early trial
NCT ID NCT05347225
First seen May 12, 2026 · Last updated Jun 16, 2026 · Updated 9 times
Summary
This early-stage study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to prior therapies. The main goals are to check the drug's safety and how the body processes it. Researchers will also look for signs that the drug is shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong Provincial People's Hospital-hematology department ( Site 1002)
Guangzhou, Guangdong, 510080, China
-
Henan Cancer Hospital-hematology department ( Site 1003)
Zhengzhou, Henan, 450008, China
-
Hunan Cancer Hospital ( Site 1004)
Changsha, Hunan, 410013, China
-
Institute of hematology&blood disease hospital-Hematology ( Site 1001)
Tianjin, Tianjin Municipality, 301636, China
-
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007)
Guangzhou, Guangdong, 511400, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.